Brief: Elicera Therapeutics Reports Additional Signals Of Clinical Activity In ELC-100 Study

Elicera Therapeutics AB

07/12/2022 14:36

Dec 7 (Reuters) - Elicera Therapeutics AB  ELIC.ST :
    * ELICERA THERAPEUTICS REPORTS ADDITIONAL SIGNALS OF
CLINICAL
ACTIVITY IN PATIENTS TREATED FOR NEUROENDOCRINE TUMORS IN THE
ELC-100 STUDY AT THE ONCOLYTIC VIROTHERAPY SUMMIT IN BOSTON
    * ALL PATIENTS EVALUATED TO DATE SHOW DISEASE PROGRESSION,
CLINICAL ACTIVITY DEMONSTRATED IN TWO PATIENTS IS BASED ON
REDUCTION IN SOME, BUT NOT ALL, METASTASES
    * REPORTING OF SAFETY DATA FOR THIRD PATIENT COHORT IS
EXPECTED TO
OCCUR IN Q1 OF 2023
    * FULL EFFICACY REPORTING FROM ELC-100 STUDY EXPECTED TO
OCCUR IN
2023 AT EARLIEST

Source text for Eikon:  ID:nWkr6SdWcx 
Further company coverage:  ELIC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))